NCT01184326View on ClinicalTrials.gov

Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Solid TumorKidney Cancer
Interventions
DRUG

pazopanib

DRUG

everolimus

Trial Locations (2)

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (2)

GlaxoSmithKline
Novartis
All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Novartis

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER